JP2014530875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530875A5 JP2014530875A5 JP2014537311A JP2014537311A JP2014530875A5 JP 2014530875 A5 JP2014530875 A5 JP 2014530875A5 JP 2014537311 A JP2014537311 A JP 2014537311A JP 2014537311 A JP2014537311 A JP 2014537311A JP 2014530875 A5 JP2014530875 A5 JP 2014530875A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fatty acid
- composition according
- drug
- acid diester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 109
- 239000000194 fatty acid Substances 0.000 claims description 109
- 239000008194 pharmaceutical composition Substances 0.000 claims description 95
- 229920001223 polyethylene glycol Polymers 0.000 claims description 94
- 150000004665 fatty acids Chemical class 0.000 claims description 81
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical group CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 54
- 239000003814 drug Substances 0.000 claims description 43
- 229940079593 drugs Drugs 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 37
- 239000011780 sodium chloride Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 31
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 239000000654 additive Substances 0.000 claims description 19
- HVFLCNVBZFFHBT-ZKDACBOMSA-N Cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims description 17
- 230000000996 additive Effects 0.000 claims description 17
- 229960002100 cefepime Drugs 0.000 claims description 17
- 150000001780 cephalosporins Chemical class 0.000 claims description 16
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 16
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 12
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims description 10
- 230000035536 Oral bioavailability Effects 0.000 claims description 6
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 6
- 230000036220 oral bioavailability Effects 0.000 claims description 6
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 5
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 125000000185 sucrose group Chemical group 0.000 claims description 5
- 229960003644 Aztreonam Drugs 0.000 claims description 4
- WZPBZJONDBGPKJ-VEHQQRBSSA-N Aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 4
- 206010060945 Bacterial infection Diseases 0.000 claims description 4
- ZCCUWMICIWSJIX-NQJJCJBVSA-N Ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 claims description 4
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 claims description 4
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims description 4
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 4
- 229940049954 Penicillin Drugs 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- 229960000626 benzylpenicillin Drugs 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- JSVCEVCSANKFDY-SFYZADRCSA-N carbacephem Chemical compound C1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C)[C@H]21 JSVCEVCSANKFDY-SFYZADRCSA-N 0.000 claims description 4
- RGFBRLNVZCCMSV-BIRGHMBHSA-N ceftaroline Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(N)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 RGFBRLNVZCCMSV-BIRGHMBHSA-N 0.000 claims description 4
- 229940036735 ceftaroline Drugs 0.000 claims description 4
- 229960004828 ceftaroline fosamil Drugs 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 229960002770 ertapenem Drugs 0.000 claims description 4
- 229960002260 meropenem Drugs 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 4
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 208000002633 Febrile Neutropenia Diseases 0.000 claims description 3
- 206010046577 Urinary tract infection Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000014666 liquid concentrate Nutrition 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- AVAACINZEOAHHE-VFZPANTDSA-N Doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 2
- 229960000895 doripenem Drugs 0.000 claims 2
- 229920001451 Polypropylene glycol Polymers 0.000 description 73
- -1 fatty acid esters Chemical class 0.000 description 37
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 210000003491 Skin Anatomy 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 201000003984 candidiasis Diseases 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 206010007134 Candida infection Diseases 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- XAKKNLNAJBNLPC-MAYKBZFQSA-N (6R,7R)-3-[(E)-3-[(2-amino-2-oxoethyl)-ethyl-methylazaniumyl]prop-1-enyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)/C=C/C[N+](C)(CC)CC(N)=O)C([O-])=O)C(=O)C(=N/OCF)\C1=NSC(N)=N1 XAKKNLNAJBNLPC-MAYKBZFQSA-N 0.000 description 2
- DKOQGJHPHLTOJR-PUIFZAHNSA-N (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-PUIFZAHNSA-N 0.000 description 2
- HCCFUFNFJIUPHS-MZYBJUSBSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-3-[(1-methylpyridin-1-ium-4-yl)sulfanylmethyl]-5,8-dioxo-5$l^{4}-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound C1=C[N+](C)=CC=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C=3N=C(N)SC=3)[C@H]2S(=O)C1 HCCFUFNFJIUPHS-MZYBJUSBSA-O 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 2
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 229940091771 Aspergillus fumigatus Drugs 0.000 description 2
- 229960000466 CEFPIROME Drugs 0.000 description 2
- FMZXNVLFJHCSAF-DNVCBOLYSA-N Cefalonium Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 description 2
- 229950001334 Cefluprenam Drugs 0.000 description 2
- 229950004036 Cefpimizole Drugs 0.000 description 2
- LNZMRLHZGOBKAN-KAWPREARSA-N Cefpimizole Chemical compound N1=CNC(C(=O)N[C@@H](C(=O)N[C@@H]2C(N3C(=C(C[N+]=4C=CC(CCS(O)(=O)=O)=CC=4)CS[C@@H]32)C([O-])=O)=O)C=2C=CC=CC=2)=C1C(=O)O LNZMRLHZGOBKAN-KAWPREARSA-N 0.000 description 2
- 229950009592 Cefquinome Drugs 0.000 description 2
- 229960000484 Ceftazidime Drugs 0.000 description 2
- 229940106196 Cephaloridine Drugs 0.000 description 2
- CZTQZXZIADLWOZ-CRAIPNDOSA-N Cephaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229950008882 Polysorbate Drugs 0.000 description 2
- 201000005661 acute cystitis Diseases 0.000 description 2
- 229960003866 cefaloridine Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 206010000269 Abscess Diseases 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 229960003348 Anidulafungin Drugs 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 206010003486 Aspergillus infection Diseases 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 210000000013 Bile Ducts Anatomy 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 206010005940 Bone and joint infection Diseases 0.000 description 1
- 240000008923 Camelina sativa Species 0.000 description 1
- 229940095731 Candida albicans Drugs 0.000 description 1
- 241000144583 Candida dubliniensis Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N Caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 229960003034 Caspofungin Drugs 0.000 description 1
- 206010061036 Central nervous system infection Diseases 0.000 description 1
- 241001508813 Clavispora lusitaniae Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 206010014665 Endocarditis Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 229940045505 Klebsiella pneumoniae Drugs 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 206010024971 Lower respiratory tract infection Diseases 0.000 description 1
- 206010061229 Lung infection Diseases 0.000 description 1
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 1
- 229960002159 Micafungin Drugs 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033767 Paracoccidioides infection Diseases 0.000 description 1
- 206010034674 Peritonitis Diseases 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940055033 Proteus mirabilis Drugs 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 229940076185 Staphylococcus aureus Drugs 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229940031000 Streptococcus pneumoniae Drugs 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229940076156 Streptococcus pyogenes Drugs 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 210000001635 Urinary Tract Anatomy 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- FBCLKBXYZRAXNA-PDIPHZEPSA-N aculeacin A Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCCCCCCCC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 FBCLKBXYZRAXNA-PDIPHZEPSA-N 0.000 description 1
- 108010081349 aculeacin A Proteins 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 201000002909 aspergillosis Diseases 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 201000001178 bacterial pneumonia Diseases 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- FAUOJMHVEYMQQG-HVYQDZECSA-N echinocandin B Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)=CC=C(O)C=C1 FAUOJMHVEYMQQG-HVYQDZECSA-N 0.000 description 1
- 108010062092 echinocandin B Proteins 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 201000003928 fungal infectious disease Diseases 0.000 description 1
- 201000002563 histoplasmosis Diseases 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 201000000301 paracoccidioidomycosis Diseases 0.000 description 1
- 201000006518 pelvic inflammatory disease Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 201000007096 vulvovaginal candidiasis Diseases 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161549882P | 2011-10-21 | 2011-10-21 | |
US61/549,882 | 2011-10-21 | ||
PCT/US2012/061125 WO2013059664A1 (en) | 2011-10-21 | 2012-10-19 | Pharmaceutical compositions and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018029249A Division JP2018109037A (ja) | 2011-10-21 | 2018-02-22 | 医薬組成物及びそれらの使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014530875A JP2014530875A (ja) | 2014-11-20 |
JP2014530875A5 true JP2014530875A5 (US20030027995A1-20030206-C00005.png) | 2015-12-03 |
JP6329486B2 JP6329486B2 (ja) | 2018-05-23 |
Family
ID=48141411
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014537311A Expired - Fee Related JP6329486B2 (ja) | 2011-10-21 | 2012-10-19 | 医薬組成物及びそれらの使用 |
JP2018029249A Withdrawn JP2018109037A (ja) | 2011-10-21 | 2018-02-22 | 医薬組成物及びそれらの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018029249A Withdrawn JP2018109037A (ja) | 2011-10-21 | 2018-02-22 | 医薬組成物及びそれらの使用 |
Country Status (5)
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6329486B2 (ja) * | 2011-10-21 | 2018-05-23 | シーチェイド ファーマシューティカルズ,インコーポレーテッド | 医薬組成物及びそれらの使用 |
US20160074322A1 (en) * | 2013-04-25 | 2016-03-17 | Seachaid Pharmaceuticals, Inc. | Oral cefepime compositions and uses thereof |
WO2021006267A1 (ja) * | 2019-07-08 | 2021-01-14 | グリーン・テック株式会社 | ピラゾール誘導体の塩及びピラゾール誘導体の製剤 |
CN111053755B (zh) * | 2019-12-31 | 2022-03-29 | 金日制药(中国)有限公司 | 一种高渗透性的头孢克肟胶囊制剂制备方法 |
CN111450057A (zh) * | 2020-06-03 | 2020-07-28 | 江苏中牧倍康药业有限公司 | 一种硫酸头孢喹肟自微乳及其制备方法 |
AU2021104067A4 (en) * | 2021-07-12 | 2021-09-09 | Pharmachem Australia Pty Ltd | Oral antibiotic formulation |
WO2023178324A1 (en) | 2022-03-17 | 2023-09-21 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising salts of salcaprozate and nicotinamide for improving oral bioavailability |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57146722A (en) * | 1981-03-06 | 1982-09-10 | Toyo Jozo Co Ltd | Pharmaceutical preparation having improved absorption |
US4537772A (en) | 1984-05-02 | 1985-08-27 | Merck & Co., Inc. | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines |
JPS61267528A (ja) | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | 吸収促進剤を含有するカルシトニン経鼻剤 |
JP3440315B2 (ja) * | 1994-12-02 | 2003-08-25 | 小林製薬株式会社 | トイレ用洗浄剤組成物 |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7235583B1 (en) * | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
WO2004002458A1 (en) * | 2002-06-28 | 2004-01-08 | Shire Laboratories Inc. | Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
JP4829783B2 (ja) | 2003-06-24 | 2011-12-07 | バイオコン・リミテッド | カルシトニン薬−オリゴマーコンジュゲートの混合物および疼痛治療における使用方法 |
US20050123602A1 (en) * | 2003-09-25 | 2005-06-09 | Michaelis Arthur F. | Rifalazil formulations |
US8329958B2 (en) | 2004-07-02 | 2012-12-11 | Biocon Limited | Combinatorial synthesis of PEG oligomer libraries |
AU2006242535B2 (en) * | 2005-04-29 | 2012-08-09 | Merck Sharp & Dohme Corp. | Therapeutic compositions |
JP4343153B2 (ja) | 2005-05-12 | 2009-10-14 | 基博 中島 | 抗腫瘍組成物の製造方法 |
US20080145411A1 (en) | 2006-10-06 | 2008-06-19 | Kaneka Corporation | Composition of high absorbability for oral administration comprising oxidized coenzyme q10 |
MX2009006912A (es) * | 2006-12-28 | 2009-08-12 | Repros Therapeutics Inc | Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas. |
US8362083B2 (en) * | 2008-01-15 | 2013-01-29 | C.B. Fleet Company Inc. | Taste-masked docusate compositions |
WO2009131995A1 (en) | 2008-04-21 | 2009-10-29 | Nanobio Corporation | Nanoemulsion influenza vaccine |
US9241519B2 (en) | 2008-09-19 | 2016-01-26 | Ironclad Performance Wear Corporation | Glove for use in the oil and natural gas extraction industries |
EP2338480A1 (en) * | 2009-12-22 | 2011-06-29 | LEK Pharmaceuticals d.d. | Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt |
JP6329486B2 (ja) * | 2011-10-21 | 2018-05-23 | シーチェイド ファーマシューティカルズ,インコーポレーテッド | 医薬組成物及びそれらの使用 |
US20160074322A1 (en) | 2013-04-25 | 2016-03-17 | Seachaid Pharmaceuticals, Inc. | Oral cefepime compositions and uses thereof |
-
2012
- 2012-10-19 JP JP2014537311A patent/JP6329486B2/ja not_active Expired - Fee Related
- 2012-10-19 US US14/352,966 patent/US9308263B2/en not_active Expired - Fee Related
- 2012-10-19 WO PCT/US2012/061125 patent/WO2013059664A1/en active Application Filing
- 2012-10-19 IN IN3214CHN2014 patent/IN2014CN03214A/en unknown
- 2012-10-19 EP EP12841549.4A patent/EP2775831A4/en not_active Withdrawn
-
2018
- 2018-02-22 JP JP2018029249A patent/JP2018109037A/ja not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014530875A5 (US20030027995A1-20030206-C00005.png) | ||
JP2018109037A (ja) | 医薬組成物及びそれらの使用 | |
Rauseo et al. | Hope on the horizon: novel fungal treatments in development | |
JP7177314B2 (ja) | セフトロザン抗生物質組成物 | |
Levi et al. | Oral infections and antibiotic therapy | |
US20070231406A1 (en) | Use of gallium to treat biofilm-associated infections | |
US8461143B2 (en) | Stabilizing compositions for antibiotics and methods of use | |
US20100197650A1 (en) | Compositions and methods of treatment comprising ceftaroline | |
ES2965017T3 (es) | Micropartículas que comprenden un compuesto que contiene azufre | |
Fassbender et al. | Pharmacokinetics of new oral cephalosporins, including a new carbacephem | |
Karras et al. | Novel antimicrobial agents against multi-drug-resistant Gram-negative bacteria: An overview | |
CN113194943B (zh) | 一种具有稳定性和抑菌活性的含有头孢噻肟舒巴坦或头孢噻肟他唑巴坦的药物组合物 | |
ES2428167T3 (es) | Composición farmacéutica bactericida activa anti-MRSA conteniendo carbapenemos | |
Horcajada et al. | Future alternatives for the treatment of infections caused by carbapenemase-producing Enterobacteriaceae: What is in the pipeline? | |
Macesic et al. | Nystatin | |
Serris et al. | New approaches to manage infections in transplant recipients: report from the 2023 GTI (infection and transplantation group) annual meeting | |
ALBAYRAK et al. | Mikrobiyal Biyofilm Kontrolünde Lipozom Bazlı İlaç Taşıyıcı Sistemler | |
CN117281812A (zh) | 抗菌组合物和抗菌药物 | |
AU2014200107B2 (en) | Compositions and methods of treatment comprising ceftaroline | |
Cole et al. | Anti-infective innovations: highlights from the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) | |
EA039441B1 (ru) | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения, способ ее получения и применение | |
St Germain et al. | Anidulafungin. | |
Revill et al. | Tomopenem | |
EA039541B1 (ru) | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения, способ ее получения и применение | |
Frank et al. | Antibiotics, Antimycotics: Spectrum–Dosage–Adverse Effects–Costs |